DS-2330b PIB + Placebo + Sevelamer + DS-2330b Tablet
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Aug 17, 2017 → Jan 3, 2019
NCT ID
NCT03305471About DS-2330b PIB + Placebo + Sevelamer + DS-2330b Tablet
DS-2330b PIB + Placebo + Sevelamer + DS-2330b Tablet is a phase 1 stage product being developed by Daiichi Sankyo for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03305471. Target conditions include Hyperphosphatemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03305471 | Phase 1 | Completed |
Competing Products
20 competing products in Hyperphosphatemia